Home Health Why a U.K. pharma giant is paying a 40% premium to pivot...
Health

Why a U.K. pharma giant is paying a 40% premium to pivot back to oncology

Why a U.K. pharma giant is paying a 40% premium to pivot back to oncology
Key Points

U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.

U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
U.K. (LOCATION) GSK (ORG) Nuvalent (ORG)
Originally published by MarketWatch Read original →